Treace Medical sees Q4 revenue $62.1M-$62.5M, consensus $61.76M

New active surgeon additions of approximately 202 for full-year 2025; ended the year with approximately 3,337 active surgeons, a 6% increase compared to the prior year and approximately 33% of the estimated 10,000 U.S. surgeons performing bunion surgery. “Despite top-line headwinds, we are encouraged by our fourth-quarter progress. Surgeon adoption of our expanded suite of 3D bunion technologies again drove mid-single-digit case volume growth in the quarter,” said John T. Treace, CEO and Chairman of Treace. “Supported by our dedicated, bunion-focused sales force, these technologies position us to further penetrate the bunion market and expand our surgeon customer base. We maintain a leading position in the bunion market and remain focused on expanding our share of the bunion procedure market, improving profitability, and delivering long-term value to shareholders.”